Analgesic efficacy and potency of two oral controlled-release morphine preparations
Autor: | James Komorowski, Jeanette Mitchell, Tom P Barden, Robert F. Kaiko, Paul Goldenheim, Gail B Cissell, Saul S Bloomfield, Ronald D. Fitzmartin, R. Grandy |
---|---|
Rok vydání: | 1993 |
Předmět: |
Adult
Randomization Adolescent Visual analogue scale Analgesic Administration Oral law.invention Double-Blind Method Oral administration law medicine Humans Potency Pharmacology (medical) Pharmacology Analysis of Variance Pain Postoperative Clinical pharmacology Morphine business.industry Confidence interval Delayed-Action Preparations Anesthesia Female Analgesia business medicine.drug |
Zdroj: | Clinical Pharmacology and Therapeutics. 53:469-478 |
ISSN: | 1532-6535 0009-9236 |
DOI: | 10.1038/clpt.1993.53 |
Popis: | MS Contin tablets and Oramorph SR tablets are two forms of oral controlled-release morphine sulfate available for the alleviation of pain. Our objective was to compare their analgesic effects in a relative potency assay. In this study, 151 patients undergoing caesarean section or abdominal hysterectomy and reporting moderate or severe postoperative pain received a 30 or 90 mg dose of either drug in a balanced, randomized, double-blind, parallel-group, single-dose experimental design. Patients provided self-ratings of analgesia. Relative potency for pain relief were calculated from log dose-effect curves. For total pain relief (rated by visual analog scales) over 12 hours, the log dose relative potency estimate for MS Contin tablets/Oramorph SR tablets was 1.9 (95% confidence limits, 0.89 to 11.1); for peak pain relief (visual analog scales) the relative potency estimate was 1.7 (95% confidence limits, 0.65 to 48.3). Overall, the 90 mg dose of MS Contin was more effective than 30 or 90 mg doses of Oramorph SR and the 30 mg dose of MS Contin at hours 6 to 12. Adverse experiences (mainly drowsiness) were mostly mild to moderate, with no significant differences in their overall incidence or severity between equivalent doses. MS Contin tablets provided greater peak, total, and duration of analgesia, without higher incidence of adverse experiences. Clinical Pharmacology and Therapeutics (1993) 53, 469–478; doi:10.1038/clpt.1993.53 |
Databáze: | OpenAIRE |
Externí odkaz: |